0000000000102008

AUTHOR

D. Bartolozzi

showing 3 related works from this author

Validity and reliability of the Italian version of the Chronic Liver Disease Questionnaire (CLDQ-I) for the assessment of health-related quality of l…

2005

Background.: The Chronic Liver Disease Questionnaire is a specific health-related quality of life assessment designed for patients with liver diseases. Aim.: The aim of this paper is to report on the validity, reliability and sensitivity to change of the Italian version (Chronic Liver Disease Questionnaire-I) in subjects with HCV infection. Subjects.: The Chronic Liver Disease Questionnaire-I was administered to 350 subjects with HCV infection together with the World Health Organization Quality of Life Assessment, abbreviated version, a generic quality of life assessment. Methods.: The instrument was translated from English, backtranslated and reviewed in focus groups in the framework of a …

liver disease; liver-specific quality of life; quality of life; questionnaireQuestionnairesQuality of lifemedicine.medical_specialtyPsychometricsPsychometricsValidityChronic liver diseaseLiver diseaseQuality of life (healthcare)Surveys and QuestionnairesmedicineHealth Status IndicatorsHumansMulticenter Studies as TopicSurveys and QuestionnaireHealth Status IndicatorChronicReliability (statistics)Health related quality of lifeChronic Disease Health Status Indicators Hepatitis C; Chronic Humans Italy Liver Diseases Multicenter Studies as Topic Psychometrics Quality of Life QuestionnairesHepatologybusiness.industryQuestionnaireLiver DiseasesLiver DiseaseGastroenterologyHepatitis C Chronicmedicine.diseaseHepatitis CExploratory factor analysisItalyLiver-specific quality of lifeChronic DiseasePhysical therapybusinessPsychometricHuman
researchProduct

Therapy expectations and physical comorbidity affect quality of life in chronic hepatitis C virus infection.

2007

Summary.  Hepatitis C virus (HCV) infection is associated with a significant reduction of health related quality of life (QOL), the causes and mechanisms of which are still unknown. To explore whether treatment history could affect QOL, we examined patients with detectable HCV viraemia who had a different therapeutic background. Two hundred sixty-four consecutive subjects with chronic HCV infection and detectable viraemia were enrolled. Of these, 163 were untreated patients, 43 were relapsers, 58 were nonresponders (NR) to nonpegylated interferon (IFN) therapy. To assess QOL, three self-report instruments were employed: the Short Form-36 (SF-36), the Chronic Liver Disease Questionnaire (CLD…

AdultMaleQuestionnairesmedicine.medical_specialtyHealth StatusHepatitis C virusComorbidityAffect (psychology)Chronic liver diseasemedicine.disease_causeliver-specific quality of life nonresponse to treatment physical comorbidity quality of lifeWorld healthVirusQUALITY OF LIFEChronic hepatitisQuality of lifeSurveys and QuestionnairesVirologyInternal medicineHumansMedicineChronicAgedHepatologybusiness.industryHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CComorbidityhumanitiesAdult Aged Comorbidity Female Health Status Hepatitis C; Chronic; drug therapy/virology Humans Interferons; therapeutic use Linear Models Male Middle Aged Quality of Life Questionnairesdrug therapy/virologyInfectious Diseasestherapeutic useHCVLinear ModelsPhysical therapyFemaleInterferonsbusiness
researchProduct

Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data

2019

OBJECTIVE:\ud We estimated the cost consequence of Italian National Health System (NHS) investment in direct-acting antiviral (DAA) therapy according to hepatitis C virus (HCV) treatment access policies in Italy.\ud \ud METHODS:\ud A multistate, 20-year time horizon Markov model of HCV liver disease progression was developed. Fibrosis stage, age and genotype distributions were derived from the Italian Platform for the Study of Viral Hepatitis Therapies (PITER) cohort. The treatment efficacy, disease progression probabilities and direct costs in each health state were obtained from the literature. The break-even point in time (BPT) was defined as the period of time required for the cumulativ…

Liver CirrhosisPediatricsTime FactorsSettore MED/09 - Medicina InternaNational Health ProgramsERADICATIONOUTBREAKantiviral treatment anti HCV economic consequencesHepacivirusLIVER FIBROSISSeverity of Illness IndexHealth Services AccessibilityCOST-EFFECTIVENESSIndirect costs0302 clinical medicineEpidemiologyvirus infection030212 general & internal medicinehealth care economics and organizationscost effectiveness030503 health policy & servicesHealth PolicyHealth services researchhealthHepatitis CHepatitis CMarkov Chainschronic hepatitis C virus infection fibrosis progression cost effectiveness liver fibrosisItalyPharmacology; Health Policy; Public Health Environmental and Occupational HealthCohortSettore SECS-P/03 - Scienza delle FinanzeDisease ProgressionPublic Health0305 other medical scienceViral hepatitisAnti-HCV antiviral treatmentCHRONIC HEPATITIS-Cmedicine.medical_specialtyGenotypeSettore MED/12 - GASTROENTEROLOGIAVIRUS-INFECTIONAntiviral AgentsNO03 medical and health sciencesCost SavingsAntiviral Agents; Cost Savings; Disease Progression; Genotype; Health Policy; Health Services Accessibility; Hepacivirus; Hepatitis C; Humans; Italy; Liver Cirrhosis; Markov Chains; National Health Programs; Severity of Illness Index; Time FactorsmedicineMANAGEMENTHumanschronic hepatitis CINDUCED DISEASESMETAANALYSISPharmacologyHealth economicsbusiness.industryPublic healthEnvironmental and Occupational HealthPublic Health Environmental and Occupational Healthmedicine.diseaseFIBROSIS PROGRESSIONbusiness
researchProduct